Cover Image
市場調查報告書

骨折:開發中產品分析

Bone Fracture - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 271824
出版日期 內容資訊 英文 107 Pages
訂單完成後即時交付
價格
Back to Top
骨折:開發中產品分析 Bone Fracture - Pipeline Review, H1 2017
出版日期: 2017年03月31日 內容資訊: 英文 107 Pages
簡介

所謂骨折,是受到超過骨組織強度的衝擊而造成骨頭斷裂。主要的症狀、跡象是骨折部位腫大,紫斑出現,手臂、骨頭變形,損傷的部分喪失功能,複雜骨折的情況是骨頭刺出皮膚等。

本報告提供全球各國的骨折治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

骨折概要

治療藥的開發

  • 骨折的開發中產品:概要
  • 骨折的開發中產品:比較分析

各企業開發中的骨折治療藥

大學/研究機關研究中的骨折治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

骨折治療藥:開發中的產品一覽(各企業)

骨折治療藥:研究中的產品一覽(各大學/研究機關)

骨折開發治療藥的企業

  • Arcarios BV
  • AstraZeneca Plc
  • Biogenomics Limited
  • BiologicsMD, Inc.
  • Biopharm GmbH
  • Bone Therapeutics SA
  • ethris GmbH
  • Juventas Therapeutics, Inc.
  • Kuros Biosciences AG
  • Novartis AG
  • TissueGene, Inc.
  • Viking Therapeutics, Inc.

骨折:治療藥的評估

  • 單劑治療藥的情況
  • 各標的
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • ALLOB
  • AZD-2858
  • bimagrumab
  • BMD-1221
  • Cyndacel-M
  • denosumab biosimilar
  • dibotermin alfa
  • Drugs to Modulate Bone Morphogenetic Protein for Osteoarthritis and Fracture
  • Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders
  • Gene Therapy for Bone Fracture
  • JVS-200
  • KAL-436
  • KUR-111
  • KUR-113
  • LWnt-3a
  • Oligonucleotide to Activate BMP-2 for Bone Fracture
  • Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease
  • Recombinant Protein to Activate TNF-Alpha for Fracture Repair
  • Small Molecules for Immunology, Metabolic and Musculoskeletal Disorders
  • Small Molecules for Immunology, Musculoskeletal and Metabolic Disorders
  • Stem Cell Therapy for Fracture Repair
  • Synthetic Peptide for Osteoporosis and Bone Fracture
  • TG-B
  • VK-5211

骨折治療藥:開發中產品的最新趨勢

骨折治療藥:開發暫停的產品

骨折相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿(1件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9134IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Fracture - Pipeline Review, H1 2017, provides an overview of the Bone Fracture (Musculoskeletal Disorders) pipeline landscape.

Fractures are simply a break in a bone caused by forces that exceed the strength of the osseous tissue in the bone. Signs and symptoms of a fracture include swelling or bruising over a bone, deformity of an arm or leg, loss of function in the injured area and in compound fractures, bone protruding from the skin.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bone Fracture - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Bone Fracture (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Fracture (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Bone Fracture and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 1, 16 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.

Bone Fracture (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Fracture (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Bone Fracture (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bone Fracture (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bone Fracture (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bone Fracture (Musculoskeletal Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bone Fracture (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bone Fracture (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bone Fracture - Overview
    • Bone Fracture - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Bone Fracture - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Bone Fracture - Companies Involved in Therapeutics Development
    • American Gene Technologies International Inc
    • Arcarios BV
    • AstraZeneca Plc
    • Biogenomics Ltd
    • BiologicsMD Inc
    • Biopharm GmbH
    • Bone Therapeutics SA
    • Cellmid Ltd
    • Chrysalis BioTherapeutics Inc
    • Entera Bio Ltd
    • Escape Therapeutics Inc
    • ethris GmbH
    • Kuros Biosciences AG
    • Novartis AG
    • Pluristem Therapeutics Inc
    • TissueGene Inc
    • Viking Therapeutics Inc
  • Bone Fracture - Drug Profiles
    • ALLOB - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZD-2858 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bimagrumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMD-1221 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cannabidiol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cyndacel-M - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • denosumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dibotermin alfa biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Modulate Bone Morphogenetic Protein for Osteoarthritis and Fracture - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Bone Fracture - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Bone Fracture - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate BMP2 and VEGF for Bone Fracture - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KAL-436/9 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KUR-111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KUR-113 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LWnt-3a - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Midkine for Bone Fractures - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotide to Activate BMP-2 for Bone Fracture - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OsteoStem - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PLX-PAD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Peptide to Agonize PTH1R for Bone Fracture - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rusalatide acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Metabolic and Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Musculoskeletal and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SPI-86 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Fracture Repair - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide for Osteoporosis and Bone Fracture - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TG-B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VK-5211 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Bone Fracture - Dormant Projects
  • Bone Fracture - Discontinued Products
  • Bone Fracture - Product Development Milestones
    • Featured News & Press Releases
      • Mar 09, 2017: Bone Therapeutics Completes Recruitment of 16 Patients in ALLOB PHASE I/IIA Delayed-Union Study
      • Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spinal fusion trial
      • Sep 01, 2016: Viking Therapeutics Presents Phase 1 Data and Highlights Ongoing Phase 2 Study of VK5211 at 5th Fragility Fracture Network Global Congress 2016
      • Aug 09, 2016: Cellmid: New Publication For Cellmid Midkine Antibody
      • Jun 24, 2016: Cellmid: New Publication And Patent Application For Midkine Antibody
      • May 03, 2016: Bone Therapeutics completes recruitment of its ALLOB Phase IIA spinal fusion study
      • Feb 24, 2016: Bone Therapeutics Presents ALLOB Pre-Clinical and Early Clinical Efficacy Data in Spinal Fusion at the 'Clinical Applications of Stem Cells' Conference
      • Feb 17, 2016: Bone Therapeutics treats 12 patients without safety concerns in ALLOB Phase IIA spinal fusion trial
      • Nov 03, 2015: Viking Therapeutics Initiates Phase 2 Trial of VK5211 in Patients Recovering From Hip Fracture
      • Oct 20, 2015: Viking Therapeutics Completes Safety, Tolerability and Pharmacokinetic Study of VK5211, a Selective Androgen Receptor Modulator, in Healthy Elderly Subjects
      • Oct 09, 2015: Kuros Presents Results of Phase IIB Study with KUR-111 at the 2015 Orthopaedic Trauma Association Annual Meeting
      • Sep 01, 2015: Viking Therapeutics Initiates Clinical Trial for VK5211, a Selective Androgen Receptor Modulator, for Acute Hip Fracture
      • Jul 14, 2015: Viking Therapeutics Submits Investigational New Drug (IND) Application for VK5211, a Selective Androgen Receptor Modulator (SARM), in Acute Hip Fracture
      • Mar 23, 2015: Bone Therapeutics treats first patients in ALLOB Phase IIA spinal fusion trial
      • Jan 19, 2015: Bone Therapeutics Demonstrates Efficacy in First Patient Cohort in ALLOB Phase I/IIA Delayed-Union Trial
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Bone Fracture, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Bone Fracture - Pipeline by American Gene Technologies International Inc, H1 2017
  • Bone Fracture - Pipeline by Arcarios BV, H1 2017
  • Bone Fracture - Pipeline by AstraZeneca Plc, H1 2017
  • Bone Fracture - Pipeline by Biogenomics Ltd, H1 2017
  • Bone Fracture - Pipeline by BiologicsMD Inc, H1 2017
  • Bone Fracture - Pipeline by Biopharm GmbH, H1 2017
  • Bone Fracture - Pipeline by Bone Therapeutics SA, H1 2017
  • Bone Fracture - Pipeline by Cellmid Ltd, H1 2017
  • Bone Fracture - Pipeline by Chrysalis BioTherapeutics Inc, H1 2017
  • Bone Fracture - Pipeline by Entera Bio Ltd, H1 2017
  • Bone Fracture - Pipeline by Escape Therapeutics Inc, H1 2017
  • Bone Fracture - Pipeline by ethris GmbH, H1 2017
  • Bone Fracture - Pipeline by Kuros Biosciences AG, H1 2017
  • Bone Fracture - Pipeline by Novartis AG, H1 2017
  • Bone Fracture - Pipeline by Pluristem Therapeutics Inc, H1 2017
  • Bone Fracture - Pipeline by TissueGene Inc, H1 2017
  • Bone Fracture - Pipeline by Viking Therapeutics Inc, H1 2017
  • Bone Fracture - Dormant Projects, H1 2017
  • Bone Fracture - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Bone Fracture, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top